Bli medlem
Bli medlem

Du är här

2016-11-03

Bactiguard Holding AB (publ): New endotracheal tube launched

Bactiguard announces the launch of its new BIP Endotracheal Tube Evac,
for prevention of ventilator associated pneumonia (VAP). It is one of
a kind and designed to offer the best infection protection available
on the market. VAP is the second most common nosocomial infection in
the ICU, and associated with high-risk pathogens such as MRSA,
prolonged hospital stay, increased hospital costs and high patient
mortality.

"We are excited to announce the launch of this unique new product,
with dual features for infection prevention. It is the only
endotracheal tube on the market with both subglottic secretion
drainage and a coating to prevent infections", says Nina Nilsson,
Director of Marketing.

"There has been a great interest from the healthcare community in our
new solution since we first exhibited it at the 29th European Society
of Intensive Care Medicine (ESICM) Annual Congress a few weeks ago",
Nina Nilsson continues.

Infections in the respiratory tract are serious and common healthcare
associated infections that affect patients using certain medical
devices, such as endotracheal tubes (ETTs). Despite limited and
relatively short, but necessary life-sustaining treatments with ETTs,
many patients develop infections in the respiratory tract -
Ventilator Associated Pneumonia (VAP).

VAP is the second most common nosocomial infection in Intensive Care
Units (ICU), and estimated to occur in up to 25% of patients1-3. It
is associated with increasing the number of days patients need to
stay in hospital by up to 25 days4, having an enormous negative
impact on patient outcomes and hospital costs. Moreover, mortality
that is directly attributable to VAP is estimated to be as high as
30-50%5-6.

The BIP Endotracheal Tube Evac offers a dual approach to the
prevention of VAP. It combines the VAP reducing mechanical feature of
subglottic secretion drainage with the clinically proven ability of
the Bactiguard coating to reduce microbial adhesion and prevention of
biofilm formation.

Microbial adhesion on the tube itself, resulting in biofilm formation
is a major cause of infection. In long-term ventilated patients,
subglottic secretions can accumulate above the cuff of the ETT and
hence, represent an ideal growth medium for bacteria. By
microaspiration along the cuff, these contaminated secretions may
pass into the lower respiratory tract and become a potential cause of
lower airway infection, including VAP. Several clinical studies have
examined the efficacy of subglottic secretion drainage and it is
found to reduce VAP by approximately 50%7.

The earlier available Bactiguard coated endotracheal tube, BIP ETT
(without subglottic suction) has been proven to reduce microbial
adhesion by up to 98% in vitro8. In addition, a clinical study on 100
patients comparing a standard uncoated endotracheal tube with BIP ETT
concluded that the Bactiguard coating reduced the incidence of VAP by
67%9.

The combination of subglottic secretion drainage and the unique
Bactiguard coating on the new tube, BIP ETT Evac, is designed to
offer the best protection against VAP available on the market.

1. Ibrahim EH et al. Chest. 2001;120(2):555-561.

2. Craven DE et al. Infect. 1996;11(1):32-53.

3. Rello J et al. Chest. 2002;122(6):2115-2121.

4. Warren DK et al. Crit Care Med. 2003;31(5):1312-1317.

5. Kollef MH et al. Chest. 2005; 128 (6): 3854-3862.

6. Stijn Blot et al. Critcal Care Medicine, March (2014) 42:3

7. Haas CF et al. Respir Care. 2014; Jun; 59(6):933-52

8. Data on file

9. Tincu R et al. Poster Euroanasthesia June (2015) 32

For further information, please contact:

Nina Nilsson, Director of Marketing

Mobile: +46 702 14 87 49

About Bactiguard

Bactiguard is a Swedish medtech company with a global presence,
offering a solution that prevents healthcare associated infections
caused by medical devices. By preventing infections, we contribute to
a reduced use of antibiotics and the spread of multi-resistant
bacteria, which is a growing problem worldwide. We save lives,
increase patient safety and significantly reduce the cost for the
healthcare and society. Our technology is well-proven, safe and
tissue friendly and consist of a thin layer of noble metals that
prevents bacterial growth. The coating can be applied on almost all
medical devices. Bactiguard-coated urinary catheters are market
leading in the US and Japan and the company has also its own product
portfolio consisting of Foley catheters, central venous catheters and
endotracheal tubes. Bactiguard is a growth company, focused on
markets in Europe, Middle East, Asia and Latin America. The company
has about 60 employees worldwide, mainly at the headquarters in
Stockholm and the production facility in Malaysia and is listed on
Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com

-----------------------------------------------------------
http://news.cision.com/bactiguard-holding-ab--publ-/r/new-endotracheal-t...
http://mb.cision.com/Main/9686/2114034/583999.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.